Cisplatin, ifosfamide, methotrexate and vinblastine combination chemotherapy for metastatic urothelial cancer

Journal of Urology

Volumn 158, Issue 2, 1997, Pages 408-411

  Kyriakakis, Zacharias ^a   Dimopoulos, Meletios A ^a   Kostakopoulos, Athanassios ^a   Karayiannis, Aristidis ^a   Sofras, Fragiskos ^a   Zervas, Anastasios ^a   Giannopoulos, Aristidis ^a   Dimopoulos, Constantinos ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Bladder; Chemotherapy; Neoplasm metastasis; Ureter; Urethra

Indexed keywords

CISPLATIN; IFOSFAMIDE; METHOTREXATE; VINBLASTINE;

AGED; ANEMIA; ARTICLE; BLADDER CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; DRUG EFFICACY; FEMALE; FEVER; GRANULOCYTOPENIA; HUMAN; MALE; METASTASIS POTENTIAL; MUCOSA INFLAMMATION; NEPHROTOXICITY; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT OUTCOME; URETER CARCINOMA; URETHRA CARCINOMA;

EID: 0030805922     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)64490-2     Document Type: Article

References (18)

1. Babaian, R. J., Johnson, D. E., Llamas, L. and Ayala, A. G.: Metastases from transitional cell carcinoma of urinary bladder. Urology, 16: 142, 1980.
2. Yagoda, A., Watson, R. C., Gonzales-Vitale, J. C., Grabstaldt, H. and Whitmore, W. F.: Cis-dichlorodiammineplatinum(II) in advanced bladder cancer. Cancer Treat. Rep., 60: 917, 1976.
3. Soloway, M. S., Ikard, M. and Ford, K.: Cisdiamminedichloroplatinum in locally advanced and metastatic transitional cell carcinoma. Cancer, 47: 476, 1981.
4. Oliver, R. T., Newlands, E. S., Wiltshaw, E. and Malpas, J. S.: A phase 2 study of cis-platinum in patients with recurrent bladder carcinoma. London and Oxford Cooperative Urological Cancer Group. Brit. J. Urol., 53: 444, 1981.
5. Harker, W. G., Meyers, F. J., Freiha, F. S., Palmer, J. M., Shortliffe, L. D., Hannigan, J. F., McWhirter, K. and Manol Torti, F. M.: Cisplatin, methotrexate and vinblastine (CMV): an effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract. A Northern California Oncology Group Study. J. Clin. Oncol., 3: 1463, 1985.
6. Sternberg, C. N., Yagoda, A., Scher, H. I., Watson, R. C., Geller, N., Herr, H. W., Morse, M. J., Sogani, P. C., Vaughan, E. D., Bander, N., Weiselberg, L., Rosado, K., Smart, T. and Lin, S.: Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium: efficacy and patterns of response and relapse. Cancer, 64: 2448, 1989.
7. Loehrer, P. J., Einhorn, L. H., Elson, P. J., Crawford, E. D., Kuebler, P., Tannock, I., Raghavan, D., Stuart-Harris, R., Sarosdy, M. F., Lowe, B. A., Blumenstein, B. and Trump, D.: A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine and doxorubicin in patients with metastatic urothelial carcinoma: A cooperative group study. J. Clin. Oncol., 10: 1066, 1992.
8. Logothetis, C. J., Dexeus, F. H., Finn, L., Sella, A., Amato, R. J., Ayala, A. G. and Kilbourn, R. G.: A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J. Clin. Oncol., 8: 1050, 1990.
9. Witte, R., Loehrer, P., Dreicer, R., Williams, S. and Elson, P.: Ifosfamide in advanced urothelial carcinoma: an ECOG trial. Proc. Amer. Soc. Clin. Oncol., 12: 230, abstract 707, 1993.
10. Einhorn, L. H., Roth, B. J., Ansari, R., Dreicer, R., Gonin, R. and Loehrer, P. J.: Phase II trial of vinblastine, ifosfamide and gallium combination chemotherapy in metastatic urothelial carcinoma. J. Clin. Oncol., 12: 2271, 1994.
11. Kaplan, E. L. and Meier, P.: Nonparametric estimation for incomplete observations. J. Amer. Stat. Ass., 53: 457, 1958.
12. Tannock, I., Gospodarowicz, M., Connoly, J. and Jewett, M.: M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) chemotherapy for transitional cell carcinoma: the Princess Margaret Hospital experience. J. Urol., 142: 289, 1989.
13. Igawa, M., Urakami, S., Shiina, H., Ishibe, T., Kadena, H. and Usui, T.: Long term results with M-VAC for advanced urothelial cancer: high relapse rate and low survival in patients with a complete response. Brit. J. Urol., 76: 321, 1995.
14. Jeffery, G. M. and Mead, G. M.: CMV chemotherapy for advanced transitional cell carcinoma. Brit. J. Cancer, 66: 542, 1992.
15. Loehrer, P. J., Sr., Elson, P., Dreicer, R., Hahn, R., Nichols, C. R., Williams, R. and Einhorn, L. H.: Escalated doses of methotrexate, vinblastine, doxorubicin and cisplatin plus recombinant human granulocyte colony-stimulating factor in advanced urothelial carcinoma: an Eastern Cooperative Oncology Group Trial. J. Clin. Oncol., 12: 483, 1994.
16. Logothetis, C. J., Finn, L. D., Smith, T., Kilbourn, R. G., Ellerhost, J. A., Zukiwsky, A. A., Sella, A., Tu, S. M. and Amato, R. J.: Escalated MVAC with or without recombinant human granulocyte-macrophage colony-stimulating factor for the initial treatment of advanced malignant urothelial tumors: results of a randomized trial. J. Clin. Oncol., 13: 2272, 1995.
17. Gad-el-Nawla, N., Hamza, M. R., Zikri, Z. K., el-Serafi, M., el-Khodary, A., Khaled, H. and Abdel-Wareth, A.: Chemotherapy in invasive carcinoma of the bladder. A review of phase II trials in Egypt. Acta Oncol., 28: 73, 1989.
18. Roth, B. J. and Bajorin, D. F.: Advanced bladder cancer: the need to identify new agents in the post-M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) world. J. Urol., part 2, 153: 894, 1995.